Effectiveness and safety of dextrose prolotherapy for chronic spinal pain: A systematic review.

IF 1.5 Q3 PHARMACOLOGY & PHARMACY
Tommy A Nazwar, Farhad Bal'afif, Donny W Wardhana, Fachriy Bal'afif, Christin Panjaitan
{"title":"Effectiveness and safety of dextrose prolotherapy for chronic spinal pain: A systematic review.","authors":"Tommy A Nazwar, Farhad Bal'afif, Donny W Wardhana, Fachriy Bal'afif, Christin Panjaitan","doi":"10.4103/joacp.joacp_524_25","DOIUrl":null,"url":null,"abstract":"<p><p>Chronic spinal pain markedly impairs function and quality of life. Dextrose prolotherapy is a potential treatment thought to induce a controlled inflammatory response, promote connective-tissue repair, enhance spinal stability, and modulate nociceptive signaling. This systematic review synthesised current evidence on its effectiveness and safety. A systematic search was performed in PubMed, ScienceDirect, SpringerLink, and the Cochrane Library up to June 2025. Eligible studies included randomized controlled trials (RCTs), prospective cohort studies, and prospective case series (≥10 patients) reporting outcomes on pain, physical function, quality of life, or adverse events. Risk of bias was assessed using Joanna Briggs Institute tools for nonrandomized studies and the Cochrane Risk of Bias 2 tool for RCTs. Twelve studies were included (six case series, two cohort studies, one quasi-experimental study, and three RCTs), involving chronic low back pain, sacroiliac joint pain, discogenic pain, coccydynia, failed back surgery syndrome, and lumbar disc herniation. Most studies reported pain reduction; intra-articular injections of 25%-50% dextrose were associated with analgesia lasting 6-24 months, whereas 5% epidural dextrose provided rapid relief in radicular pain. Improvements in physical function and quality of life were also reported, with no major complications. Overall, dextrose prolotherapy appears safe and potentially effective for chronic spinal pain, particularly in refractory cases, although outcomes may depend on patient selection, dextrose concentration, and injection technique.</p>","PeriodicalId":14946,"journal":{"name":"Journal of Anaesthesiology, Clinical Pharmacology","volume":"42 3","pages":"332-344"},"PeriodicalIF":1.5000,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13427298/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Anaesthesiology, Clinical Pharmacology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4103/joacp.joacp_524_25","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/5/19 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

Chronic spinal pain markedly impairs function and quality of life. Dextrose prolotherapy is a potential treatment thought to induce a controlled inflammatory response, promote connective-tissue repair, enhance spinal stability, and modulate nociceptive signaling. This systematic review synthesised current evidence on its effectiveness and safety. A systematic search was performed in PubMed, ScienceDirect, SpringerLink, and the Cochrane Library up to June 2025. Eligible studies included randomized controlled trials (RCTs), prospective cohort studies, and prospective case series (≥10 patients) reporting outcomes on pain, physical function, quality of life, or adverse events. Risk of bias was assessed using Joanna Briggs Institute tools for nonrandomized studies and the Cochrane Risk of Bias 2 tool for RCTs. Twelve studies were included (six case series, two cohort studies, one quasi-experimental study, and three RCTs), involving chronic low back pain, sacroiliac joint pain, discogenic pain, coccydynia, failed back surgery syndrome, and lumbar disc herniation. Most studies reported pain reduction; intra-articular injections of 25%-50% dextrose were associated with analgesia lasting 6-24 months, whereas 5% epidural dextrose provided rapid relief in radicular pain. Improvements in physical function and quality of life were also reported, with no major complications. Overall, dextrose prolotherapy appears safe and potentially effective for chronic spinal pain, particularly in refractory cases, although outcomes may depend on patient selection, dextrose concentration, and injection technique.

葡萄糖前体治疗慢性脊柱疼痛的有效性和安全性:一项系统综述。
慢性脊柱疼痛明显损害功能和生活质量。葡萄糖前体治疗被认为是一种潜在的治疗方法,可以诱导可控的炎症反应,促进结缔组织修复,增强脊柱稳定性,调节伤害性信号。本系统综述综合了目前关于其有效性和安全性的证据。系统检索PubMed、ScienceDirect、SpringerLink和Cochrane Library,检索时间截止到2025年6月。符合条件的研究包括随机对照试验(rct)、前瞻性队列研究和前瞻性病例系列(≥10例患者),报告疼痛、身体功能、生活质量或不良事件的结果。采用非随机研究的Joanna Briggs研究所工具和随机对照试验的Cochrane Risk of bias 2工具评估偏倚风险。纳入12项研究(6个病例系列、2个队列研究、1个准实验研究和3个随机对照试验),涉及慢性腰痛、骶髂关节痛、椎间盘源性疼痛、尾骨痛、背部手术失败综合征和腰椎间盘突出症。大多数研究报告疼痛减轻;关节内注射25%-50%葡萄糖与持续6-24个月的镇痛相关,而5%硬膜外葡萄糖可快速缓解神经根性疼痛。身体功能和生活质量的改善也有报道,没有重大并发症。总的来说,葡萄糖前体治疗对慢性脊柱疼痛是安全有效的,特别是在难治性病例中,尽管结果可能取决于患者选择、葡萄糖浓度和注射技术。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
1.90
自引率
6.70%
发文量
129
期刊介绍: The JOACP publishes original peer-reviewed research and clinical work in all branches of anaesthesiology, pain, critical care and perioperative medicine including the application to basic sciences. In addition, the journal publishes review articles, special articles, brief communications/reports, case reports, and reports of new equipment, letters to editor, book reviews and obituaries. It is international in scope and comprehensive in coverage.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书